Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin
in adult hospitalized patients with moderate and severe COVID-19.